MIRA Company Profile and Key Details

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) closed at $1.54 USD, losing -$0.09 (-5.52%) from the previous close of $1.63. The stock is currently mid-range between its 52-week high and low $0.73 and $2.45. With a market capitalization of about $64.47 million, MIRA Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.81). Key stats such as the average daily volume over the past year has been around 3.00 million shares, volume is running light vs its 52-week average. Headquartered in Baltimore, MD, MIRA Pharmaceuticals, Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Erez Aminov, the company employs approximately 2 people and listed since August 14, 2023. MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company.

MIRA Pharmaceuticals, Inc. generated EPS of -$1.52 over the past year. Five-year average earnings growth is -224.25%. MIRA Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 1375.0%. The prior quarter beat by 970.37%. Over the last six quarters, Apple has recorded several small beats. These include -22.22% in November 12, 2024.

MIRA has shown sold momentum, gaining 11.64% over the past week and 30.4% over the past quarter, though year-to-date performance is up 42.98%. Short-term trend indicators are mixed aligned (SMA20 10.92%, SMA50 10.13%, SMA200 22.16%). The stock’s 14-day RSI is 64.59 (firm momentum), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.47% below its high and over 123.29% above its low. Average 10-day trading volume of 421.04 thousand shares is below the 3-month average of 2.29 million, indicating normal recent market interest.

MIRA Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.18. This means the shares are trading above this model’s fair value.

MIRA Pharmaceuticals, Inc. has 19.07 million shares outstanding. The public float is 14.67 million shares, elevated short interest at 2.66% of float. This equals 388.88 thousand shares. The short ratio is 0.12 days. Institutional investors hold 6.52% of the float. Insiders own 22.37%.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares are up 42.98% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows MIRA Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -3.4. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.00, suggesting 942.94% upside. Our AI forecast model points to short-term strength (2.45% over two weeks), a medium-term fall (-44.17% over three months), and a longer-term gain (444.17% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that MIRA Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.45%, with price expected at $1.67 by January 02, 2026, within a range of $1.62 to $1.72 3-Month Outlook: Projected fall of -44.17%, reaching $0.91 by March 19, 2026, with a range of $0.76 to $1.04. 1-Year Outlook: Projected gain of 444.17%, with price at $8.87 by December 18, 2026, within a range of $6.14 to $10.36.

MIRA Pharmaceuticals, Inc. trades at a P/E ratio of -3.4, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 46.35 reflecting a rich premium to book value. The P/FCF stands at -10.71, also below market averages. Compared to sector medians, MIRA Pharmaceuticals, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.